Article info

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Authors

  1. Correspondence to Dr Masato Yoneda; yoneda-ycu{at}umin.ac.jp
View Full Text

Citation

Yoneda M, Honda Y, Ogawa Y, et al
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Publication history

  • Received November 2, 2020
  • Revised January 13, 2021
  • Accepted January 24, 2021
  • First published February 16, 2021.
Online issue publication 
February 16, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.